Clinical Utility of Bladder Cancer Biomarkers
Each year, there are an estimated 550 000 diagnoses of bladder cancer worldwide, and almost 200 000 deaths from bladder cancer. The need for frequent follow-up, including invasive procedures like cystoscopy, repetitive procedures like transurethral resection of bladder tumors and intravesical instil...
Main Author: | Laura Maria Krabbe, Georgios Gakis, Yair Lotan |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2020-10-01
|
Series: | Société Internationale d’Urologie Journal |
Subjects: | |
Online Access: | https://siuj.org/index.php/siuj/article/view/58/1 |
Similar Items
-
Clinical Utility of Oncuria™, a Multiplexed Liquid Biopsy for the Non-Invasive Detection of Bladder Cancer—A Pilot Study
by: Kaoru Murakami, et al.
Published: (2022-01-01) -
Clinical Validation of a Urine Test (Uromonitor-V2<sup>®</sup>) for the Surveillance of Non-Muscle-Invasive Bladder Cancer Patients
by: Caroline A. Sieverink, et al.
Published: (2020-09-01) -
A phase II study of neoadjuvant chemotherapy followed by organ preservation in patients with muscle-invasive bladder cancer
by: Chinna Babu Dracham, et al.
Published: (2022-07-01) -
Bladder preservation by neoadjuvant chemotherapy followed
by concurrent chemoradiation for muscle-invasive bladder cancer
by: Dalia Elsayed, et al.
Published: (2023-04-01) -
Applications of Exosomes in Diagnosing Muscle Invasive Bladder Cancer
by: Jillian Marie Walker, et al.
Published: (2022-09-01)